Zepbound (semaglutide-zsyi) is an effective treatment option for patients with chronic hepatitis C, a condition that can cause severe liver inflammation and damage
PLOS ONE 11 , e0157824 (2016)
Both were placed on FDA Category 2 in September 2023, removed in September 2024 after withdrawn nominations, and reviewed by PCAC in late 2024 with FDA recommending against 503A Bulks inclusion
While the two supplements are generally viewed as safe for a great many people, certain populations, like pregnant or lactating ladies, individuals with previous medical circumstances, or those taking drugs, should practice mindfulness and look for personalized exhortation
They were also shown to be safe in large cardiovascular outcomes trials but were not found to have cardioprotective effects [39]